Compare Crispr Therapeutics AG (CRSP) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs General Mills, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while General Mills, Inc. trades at $38.11 (market cap $20.24B). The key difference: General Mills, Inc. is far larger — about 3.9× Crispr Therapeutics AG's market cap, and General Mills, Inc. pays a 6.43% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | GIS | |
|---|---|---|
Market Cap | $5.23B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $51.11 |
52-Week Low | $44.34 | $32.17 |
Enterprise Value | $3.65B | $33.73B |
Dividend Yield | — | 6.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
General Mills (GIS) trades at $38.21, up 2.55% today, with a bullish technical signal from moving averages but mixed oscillators. Recent earnings show volatility, beating estimates in Q3 2025 and Q2 2026 but missing in Q4 2025. Revenue has declined from $20.1B in 2023 to $19.5B in 2025, with net income margin turning negative at -0.48% for 2026. The company maintains a dividend and is pursuing cost savings initiatives, while debt-to-asset ratio has risen to 45% in 2025.
Outlook is cautious; the stock offers a low P/E of 9.23 and dividend income, but faces headwinds from weak sales, margin pressure, and high debt. Analyst consensus is mixed with 22% buy, 61% hold ratings. Key risks include competitive pressures and execution of turnaround plans. Investors should weigh valuation appeal against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
